Statins May Help Block Transmission of Lyme Disease
|
By LabMedica International staff writers Posted on 27 May 2016 |

Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).
A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease.
Lyme disease is a systemic disorder caused by the spirochete bacterium Borrelia burgdorferi. This bacterium is transmitted to mammalian hosts from arthropod vectors, specifically Ixodes spp. ticks. Lyme disease is the most prevalent arthropod borne disease in the USA with over 25,000 cases confirmed by the Centers for Disease Control and Prevention in 2014.
Investigators at the University of Texas at San Antonio (USA) decided to attack B. burgdorferi through its 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, which serves as a rate limiting enzyme of the mevalonate pathway that contributes to the synthesis of components critical for building the bacterium's cell wall.
In this study C3H/HeN mice, with or without statin treatment, were infected with 1000 spirochetes per mouse. The spirochetes were found to spread to all tissues with a few exceptions. Though there was no significant difference in bacterial dissemination to distal tissues between statin-treated and untreated mice, the investigators wanted to determine whether there were differences in the numbers of bacteria migrating to specific tissues. To that end, total genomic DNA was extracted from a portion of skin, spleen, right inguinal lymph node, and right tibiotarsal joint and subjected to quantitative real-time PCR analysis using primers specific for B. burgdorferi genes.
Results published in the March 16, 2016, online edition of the journal Microbes and Infection revealed that there was a significant decrease in the numbers of bacteria in each of the tissues tested with the exception of the joints. There were higher levels of reduction seen in the lymph nodes and spleens of mice treated with simvastatin when compared to the same tissues from mice treated with lovastatin, while there was a higher level of reduction in the skin of lovastatin-treated mice.
"We have figured out that there is one enzyme in the Lyme disease bacteria that is essential for creating its cell wall, which would allow the Lyme disease bacteria to live and cause infection," said senior author Dr. Janakiram Seshu, associate professor of biology at the University of Texas at San Antonio. "We discovered that this enzyme can be inhibited by statins, which means that one class of drugs could reduce the number of infectious bacteria in the reservoir hosts. First we want to determine how statins can be used to stop the growth of the pathogen and how we can exploit these findings to our benefit. Our hope is that if we reduce the number of viable organisms in infected reservoir hosts then we can block the transmission to a point that the disease does not affect humans significantly in many areas of the USA."
Related Links:
University of Texas at San Antonio
Lyme disease is a systemic disorder caused by the spirochete bacterium Borrelia burgdorferi. This bacterium is transmitted to mammalian hosts from arthropod vectors, specifically Ixodes spp. ticks. Lyme disease is the most prevalent arthropod borne disease in the USA with over 25,000 cases confirmed by the Centers for Disease Control and Prevention in 2014.
Investigators at the University of Texas at San Antonio (USA) decided to attack B. burgdorferi through its 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, which serves as a rate limiting enzyme of the mevalonate pathway that contributes to the synthesis of components critical for building the bacterium's cell wall.
In this study C3H/HeN mice, with or without statin treatment, were infected with 1000 spirochetes per mouse. The spirochetes were found to spread to all tissues with a few exceptions. Though there was no significant difference in bacterial dissemination to distal tissues between statin-treated and untreated mice, the investigators wanted to determine whether there were differences in the numbers of bacteria migrating to specific tissues. To that end, total genomic DNA was extracted from a portion of skin, spleen, right inguinal lymph node, and right tibiotarsal joint and subjected to quantitative real-time PCR analysis using primers specific for B. burgdorferi genes.
Results published in the March 16, 2016, online edition of the journal Microbes and Infection revealed that there was a significant decrease in the numbers of bacteria in each of the tissues tested with the exception of the joints. There were higher levels of reduction seen in the lymph nodes and spleens of mice treated with simvastatin when compared to the same tissues from mice treated with lovastatin, while there was a higher level of reduction in the skin of lovastatin-treated mice.
"We have figured out that there is one enzyme in the Lyme disease bacteria that is essential for creating its cell wall, which would allow the Lyme disease bacteria to live and cause infection," said senior author Dr. Janakiram Seshu, associate professor of biology at the University of Texas at San Antonio. "We discovered that this enzyme can be inhibited by statins, which means that one class of drugs could reduce the number of infectious bacteria in the reservoir hosts. First we want to determine how statins can be used to stop the growth of the pathogen and how we can exploit these findings to our benefit. Our hope is that if we reduce the number of viable organisms in infected reservoir hosts then we can block the transmission to a point that the disease does not affect humans significantly in many areas of the USA."
Related Links:
University of Texas at San Antonio
Latest BioResearch News
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read moreMolecular Diagnostics
view channel
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
NanoSomiX, Inc. and Beckman Coulter Diagnostics announced a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases using extracellular vesicles (EVs).... Read more








